title: B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.
authors.forename: David M
authors.initials: DM
authors.lastname: Goldenberg
authors.forename: Rhona
authors.initials: R
authors.lastname: Stein
authors.forename: John P
authors.initials: JP
authors.lastname: Leonard
authors.forename: Serge D
authors.initials: SD
authors.lastname: Steinfeld
authors.forename: Thomas
authors.initials: T
authors.lastname: Dörner
authors.forename: Gerd R
authors.initials: GR
authors.lastname: Burmester
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology* / Q000473:pathology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008212:Lymphocyte Depletion; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012377:Rodentia; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C497867:CD22 protein, human; D051918:Sialic Acid Binding Ig-like Lectin 2; C448700:epratuzumab